2015
Novel Oral Anticoagulant Use Among Patients With Atrial Fibrillation Hospitalized With Ischemic Stroke or Transient Ischemic Attack
Patel P, Zhao X, Fonarow G, Lytle B, Smith E, Xian Y, Bhatt D, Peterson E, Schwamm L, Hernandez A. Novel Oral Anticoagulant Use Among Patients With Atrial Fibrillation Hospitalized With Ischemic Stroke or Transient Ischemic Attack. Circulation Cardiovascular Quality And Outcomes 2015, 8: 383-392. PMID: 26058721, PMCID: PMC4512906, DOI: 10.1161/circoutcomes.114.000907.Peer-Reviewed Original ResearchConceptsNovel oral anticoagulantsTransient ischemic attackAtrial fibrillation patientsIschemic attackIschemic strokeFibrillation patientsEligible patientsWarfarin therapyAtrial fibrillationNovel oral anticoagulant useCHA2DS2-VASc scoreRate of anticoagulationOral anticoagulant useLower stroke riskMultivariable logistic regressionAnticoagulation ratesGuidelines-StrokeNOAC useAnticoagulant useOral anticoagulantsStroke riskRisk factorsStudy populationPatterns of usePatients
2012
Risks of Intracranial Hemorrhage Among Patients With Acute Ischemic Stroke Receiving Warfarin and Treated With Intravenous Tissue Plasminogen Activator
Xian Y, Liang L, Smith E, Schwamm L, Reeves M, Olson D, Hernandez A, Fonarow G, Peterson E. Risks of Intracranial Hemorrhage Among Patients With Acute Ischemic Stroke Receiving Warfarin and Treated With Intravenous Tissue Plasminogen Activator. JAMA 2012, 307: 2600-2608. PMID: 22735429, DOI: 10.1001/jama.2012.6756.Peer-Reviewed Original ResearchConceptsIntravenous tissue plasminogen activatorInternational normalized ratioSymptomatic intracranial hemorrhageTissue plasminogen activatorSerious systemic hemorrhageIschemic strokeIntracranial hemorrhageSICH riskHospital mortalitySystemic hemorrhagePlasminogen activatorBaseline clinical factorsChronic warfarin therapyGuidelines-Stroke registrySecondary end pointsDegree of anticoagulationAmerican Heart AssociationRegistry hospitalsSICH rateSevere strokeWarfarin therapyClinical factorsComorbid conditionsHeart AssociationNormalized ratio
2008
Differential Use of Warfarin for Secondary Stroke Prevention in Patients With Various Types of Atrial Fibrillation
Lewis W, Fonarow G, LaBresh K, Cannon C, Pan W, Super D, Sorof S, Schwamm L. Differential Use of Warfarin for Secondary Stroke Prevention in Patients With Various Types of Atrial Fibrillation. The American Journal Of Cardiology 2008, 103: 227-231. PMID: 19121441, PMCID: PMC3086549, DOI: 10.1016/j.amjcard.2008.08.062.Peer-Reviewed Original ResearchConceptsECG-documented atrial fibrillationType of AFAtrial fibrillationQuality Improvement ProgramEligible patientsStroke preventionHistory of AFForm of AFSuch high-risk groupsSecondary stroke preventionTransient ischemic attackParoxysmal atrial fibrillationHigh-risk groupAnticoagulation guidelinesIschemic attackWarfarin useAnticoagulation therapyThromboembolic eventsElderly patientsHospital dischargeIschemic strokePresent admissionWarfarin therapyWarfarin treatmentMedical history